Authors’ Response - 17/02/23
| STATEMENT OF POTENTIAL CONFLICT OF INTEREST M. I. Cardel is an employee and shareholder at WW International Inc and has served as a consultant for Novo Nordisk (but did not accept personal fees for this work), all outside of the submitted work. F. A. Newsome reports personal fees from Novo Nordisk outside the submitted work, R. L. Pearl has received grant funding from WW International Inc and has served as a consultant for WW International Inc and Novo Nordisk outside of the submitted work. E. J. Dhurandhar is an employee of Obthera Inc. |
|
| FUNDING/SUPPORT R. L. Pearl is supported by a K23 award from the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) (grant no. K23HL140176). J. F. Hayes is supported by NIH NHLBI (grant nos. T32 HL076134 and K23 DK128561). K. N. Balantekin is supported by NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (grant no. K01 DK120778). P. K. Keel is supported by the NIH National Institute of Mental Health (NIMH) (grant nos. R01MH111263 and R01MH126990), and the National Cancer Institute (grant no. U54CA267730). K. M. Ross is supported by the NIDDK (grant no. R01DK119244) and NHLBI (grant no. R03HL154272). |
|
| AUTHOR CONTRIBUTIONS M. I. Cardel, J. F. Hayes, K. N. Balantekin, and F. A. Newsome drafted the manuscript. All authors participated in revision of the manuscript and final manuscript approval. |
Vol 123 - N° 3
P. 400-403 - mars 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
